EBMT 2021 | Latest developments in transplant for AML

Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, shares an overview of the latest developments in the field of transplantation for acute myeloid leukemia (AML). Prof. Nagler describes the ongoing need for transplantation in AML, due to the lack of development of novel therapies, and contrasts AML treatment to that of lymphatic malignancies for which monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies have shown promise. Prof. Nagler outlines the most recent updates in transplantation for AML, highlighting novel data investigating haploidentical transplantation without T-cell depletion, post-transplant cyclophosphamide, new compounds for treating graft-versus-host disease (GvHD), and improvements in our understanding of the microbiome. Prof. Nagler also emphasizes the importance of achieving measurable residual disease (MRD)-negativity where possible. Finally, he outlines the use of sorafenib and gliteritinib as maintenance therapies, and the development of new prognostic scores for AML assessment post-transplant. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.